Stay updated on Sepofarsen Repeat-dose in LCA10 Clinical Trial

Sign up to get notified when there's something new on the Sepofarsen Repeat-dose in LCA10 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Sepofarsen Repeat-dose in LCA10 Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:24:41.000Z thumbnail image
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    8 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy, safety, tolerability, and systemic exposure evaluation of sepofarsen (QR-110) in subjects with Leber's Congenital Amaurosis (LCA) due to the CEP290 p.Cys998X mutation after 24 months of treatment.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:16.000Z thumbnail image
  7. Check
    23 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying that researchers are looking for individuals with a clinical diagnosis of LCA10 and a molecular diagnosis of homozygosity or compound heterozygosity. Previously, this section simply stated 'No information provided.'
    Difference
    30%
    Check dated 2024-05-22T21:30:30.000Z thumbnail image
  8. Check
    45 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:54:31.000Z thumbnail image

Stay in the know with updates to Sepofarsen Repeat-dose in LCA10 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Sepofarsen Repeat-dose in LCA10 Clinical Trial page.